Skip to main content

Case Management Date Set For Taxotere Multicounty Litigation

Case Management Date Set For Taxotere Multicounty Litigation

Case Management Date Set For Taxotere Multicounty Litigation

Introduction

As per an order issued on August 24 in Middlesex County Superior court, an initial Case Management Conference for Taxotere lawsuits has been scheduled for October 4, 2018, at 10 a.m. in New Jersey.

A week prior to the conference, the parties are required to submit a brief statement with certain information to help the court identify any problems of recusal or disqualification. The parties must surrender documents related to the status of discovery, status settlement negotiations, settlement demands, mediation and prospects for settlement, along with the list of all related actions pending in the state and federal courts and their current status data. The NJ Superior County transferred 353 Taxotere hair loss cases to Middlesex County on August 15. Any lawsuit filed in New Jersey with similar claims would be included in the multicounty litigation.

Taxotere, manufactured by Sanofi-Aventis, is widely used as a chemotherapy drug. Plaintiffs across the nation allege the makers were aware of the permanent alopecia effect of the drug and failed to provide an adequate warning to doctors and patients. The multidistrict litigation (MDL No. 2740; In Re: Taxotere (Docetaxel) Products Liability Litigation) includes about 9,000 federal cases that have been centralized in the U.S. District Court, Eastern District of Louisiana for pretrial proceedings.

Comments

Restricted HTML

  • Allowed HTML tags: <a href hreflang> <em> <strong> <cite> <blockquote cite> <code> <ul type> <ol start type> <li> <dl> <dt> <dd> <h2 id> <h3 id> <h4 id> <h5 id> <h6 id>
  • Lines and paragraphs break automatically.
  • Web page addresses and email addresses turn into links automatically.

Latest News

NC to Get $150M to Boost Opioid Treatment, Recovery

Categories: Opioids

North Carolina will receive an additional $150 million from Purdue Pharma and the Sackler family as part of a national $7.4 billion settlement related to the opioid

SRI Gets FDA OK for High-Dose Naloxone Trial

Categories: Opioids

SRI has received authorization from the U.S. Food and Drug Administration (FDA) to begin Phase 1 clinical trials of a new, high-dose injectable naloxone formulation.

The approval was granted under an Investigational New Drug (IND)…

Spokane County to Get $5M in New Opioid Settlement

Categories: Opioids

Jurisdictions within Spokane County are set to receive nearly $4.7 million as part of a sweeping $7.4 billion nationwide settlement with Purdue Pharma and its owners, the Sackler family.

The agreement addresses the company’s role in fueling…

✍️ FREE—3000 Pages Medical Record Review Trial!                
No Contract. No Risk—Fully Customized, Free!

Only 10 Firms Accepted—Offer Ends June 30!